Presentation is loading. Please wait.

Presentation is loading. Please wait.

FFUL LisbonHilde Boone 29 May 2003 EMEA 1 Implementation of the CTD in Europe & EMEA Experiences Evaluation and Regulation of Medicines & Health Products.

Similar presentations


Presentation on theme: "FFUL LisbonHilde Boone 29 May 2003 EMEA 1 Implementation of the CTD in Europe & EMEA Experiences Evaluation and Regulation of Medicines & Health Products."— Presentation transcript:

1 FFUL LisbonHilde Boone 29 May 2003 EMEA 1 Implementation of the CTD in Europe & EMEA Experiences Evaluation and Regulation of Medicines & Health Products

2 Why CTD Industry initiative/request discussed at ICH level To provide for a common format/template for the submission of information to the regulatory authorities in the 3 ICH regions Common Technical Document signed-off by ICH in November 2000 2

3 Why CTD Advantages / Objectives: l Resource saving for industry l Facilitate simultaneous submission in 3 regions l Facilitate exchange of regulatory information l Harmonised format to be further supported by e-CTD l More efficient assessment; use of hyperlinks etc… l Faster availability of new medicines 3

4 Why CTD However, CTD is only a FORMAT ! Its not a single dossier, with a single content since l Legal requirements differ in the 3 regions l ICH guidelines have not yet harmonised all requirements l Pharmacopoeias are not harmonised l Applicant may have regional preferences 4

5 Modular structure of CTD Part IIPart IIIPart IV Quality Non-clinicalClinical Module 3Module 4Module 5 Module 2: written + tabular formats (replaces expert reports) Module 1: administrative, regional info (not as such part of the ICH CTD) 5

6 Modular structure of CTD Module 2: Quality Overall Summary Non-clinical Overview Clinical Overview Non-clinical Summaries (tables) Clinical Summaries (tables) To provide a summary of the development plan and of the Q, S and E data To integrate the most important information To facilitate the task of the assessor 6

7 Modular structure of CTD Module 2 should provide (a.o.): Integrated & critical analysis of the key- parameters of the product Summary and analysis of the main tox/clin data Justifications for deviations from requirements and guidelines Non-clinical and clinical strategy used by company Comment on GLP, GCP status of data submitted Benefit/risk conclusions Clear tabulated summaries of the tests/trials 7

8 Modular structure of CTD Module 3-4-5: Body of data / Study Reports + references Module 3 2 main parts: 3.2.S Drug Substance 3.2.PDrug Product Module 4-5: similar structure to current format 8

9 Quality Overall Summary 2.3 Nonclinical Overview 2.4 Clinical Overview 2.5 Nonclinical Summaries 2.6 Clinical Summary 2.7 Module 3 Quality 3.0 Module 4 Nonclinical Study Reports 4.0 Module 5 Clinical Study Reports 5.0 Module 2 CTD Table of Contents 2.1 CTD Introduction 2.2 Module 1 Regional Information 1.0 Module 2-5 CTD Module 1: Not Part of the CTD Content to be determined by EU, US, JP authorities 9

10 Implementation of CTD Each region (US, EU, Japan) to introduce CTD into legislation or guidance As of July 2003 : Mandatory use of CTD for EU, Japan (MHLW) Highly recommended for US (FDA) In EU: CTD reflected in Notice To Applicants (NTA) and in Legislation 10

11 Why CTD implemented in NTA ? old Annex I to Directive 2001/83/EC: « …. Application …. shall be presented in 4 parts…taking account of guidance published by EC in Notice To Applicants ….. » European Commission Publication (9 volumes): Rules governing medicinal products in the EU http://pharmacos.eudra.org/F2/eudralex/index.htm Volume 1 = Community legislation Volume 2 = Notice To Applicants …… 11

12 What is NTA ? Volume 2 = NTA * Volume 2A: Info on Procedures for MA (guidance, interpretation) * Volume 2B: Presentation and content of a MA dossier (format template) * Volume 2C: Regulatory guidelines First published in 1986 - Regularly updated http://pharmacos.eudra.org/F2/eudralex/vol-2/home.htm 2C 2A 2B 12

13 Current EU format for submission of applications 4 parts Replace by new format based on CTD - 5 Modules «4 parts may be presented as 5 modules» Volume 2B 2C 2A NTA NTA 5 Modules CTD CTD NTA - Volume 2B Presentation & Content 2C 2A 2B Revised NTA incorporating CTD: published 29 June 2001 13

14 Quality Overall Summary 2.3 Nonclinical Overview 2.4 Clinical Overview 2.5 Nonclinical Summaries 2.6 Clinical Summary 2.7 Module 3 Quality 3.0 Module 4 Nonclinical Study Reports 4.0 Module 5 Clinical Study Reports 5.0 Module 2 CTD Table of Contents 2.1 CTD Introduction 2.2 Module 1 Regional Information 1.0 Module 2-5 CTD Module 1: Not Part of the CTD Content to be determined by EU, US, JP authorities 14

15 NTA CTD implementation Topics to be addressed in EU l Give EU specific guidance in the Introduction l Defining scope & application types l Agree onTime frame for implementation l Defining Region-Specific items Content of Module 1 l Prepare FAQs document l Prepare amendment of Directive 2001/83/EC to legally reflect CTD structure by July 2003 15

16 NTA CTD implementation Time-Frames l NTA (CTD) Volume 2 published June 2001 l July 2001 – July 2003 : TRANSITIONAL PERIOD Dossier can be presented using the * 1998 NTA Vol. 2 B edition,or * 2001 NTA Vol. 2 B edition Mixtures of both formats between modules could be accepted, but not within parts/modules e.g. Q module 3 + S & E Parts III + IV 16

17 17 Mixed format applications See EC WebSite

18 l As of July 2003 : Mandatory for EU, Japan (MHLW) Hihgly recommended for US (FDA) l Commission to amend Relevant EU legislation to fully reflect CTD (Annex I to Dir. 2001/83/EC) New Annex I to be published SOON ! NTA CTD implementation Time-Frames 18

19 NTA CTD implementation Scope l Applicable to all types of EU procedures: - Centralised procedure - Decentralised (MR) procedure - National procedures l Applicable to all types of products: - NCEs - Biologicals, biotech - Herbal medicinal products specific guidance will be provided - OTC products 19

20 l Applicable to all types of applications: - Full, new applications - Bibliographical applications - Abridged, Generic applications - Line-extensions & Variations NTA CTD implementation Scope 20

21 Regional (EU) specific Information – Module 1 l Requirements for content of EU application: * Directive 2001/83/EC – Art. 8-12 * Directive 2001/83/EC – Annex I l Administrative and Scientific information * required by EU legislation provide in * but not reflected in CTD Module 1 21

22 Module 1 of Volume 2B (NTA) 1.1Overall Table of Contents 1.1Overall Table of Contents (complete application; modules 1-5) 1.2Application Form = current IA-form 1.3SPC, Labelling & Package Leaflet 1.4Experts 1.5Specific Requirements AnnexEnvironmental Risk Assessment 22

23 Module 1.2 Application Form Complete revision by NTA group, to reflect l Principles agreed in Chapter 1 (Vol. 2A) * Legal basis * Annex II / Line-extension l Latest MS/EMEA requirements l NEW developments: Orphan Drugs, TSE, Scientific Advice, GMOs To be used in current & new dossier format 23

24 Module 1.3 SPC/Labelling/PL * Based on EMEA/QRD Templates * National templates may apply (for MR or national procedures) In line with SPC and Readability guideline Standard headings and sentences Available in 13 languages (EMEA Web) * Mock-ups or Specimen of sales presentation 24

25 Module 1.4 Experts Art. 12 of Directive 2001/83/EC * experts must provide detailed reports on the Q, S & E data * duties of experts Annex I to Directive 2001/83/EC SIGNED expert reports « critical » evaluation 25

26 Module 1.4 Experts Expert ReportsModule 2 Overviews & Summaries SignaturesModule 1.4 Info on expertsModule 1.4 (education, experience) 26

27 Module 1.5 Specific Requirements 1.5Specific requirements for different types of applications 1.5Specific requirements for different types of applications 1. Information for bibliographical applications summary document on justification for well-established use claim 2 2. Information for generics applications summary document on evidence for essential similarity claim 27

28 l Intended for Old products; no Essential Similarity l Explain grounds for using publications Literature to be included in Module 4 and/or 5 Discussion in Module 2 (overviews and summaries; incl. WEU claims) Summary of WEU demonstration in Module 1.5 addressing each indent of of Part 3I/4I of Annex I to Dir. 2001/83/EC Well-established use (bibliographical applications) 28

29 Module 1.5: to contain summary document on: l Active substance (« same ») l Overall S/E profile l Bio-availability, Bio-equivalence Demonstrate « Essential Similarity » as defined by the NTA (chapter 1) Case-by-case validation decision by authorities Essential Similarity (generic applications) 29

30 Module 1 Annex ANNEX:Environmental Risk Assessment ANNEX:Environmental Risk Assessment (Separate binder) Incl. Risk Assessment Overview * Non GMO containing medicinal products * Medicinal product containing/consisting of GMOs There is no ANNEX II ! There is no ANNEX II ! (orphan drugs) 30

31 Questions & Answers General CTD questions & Module 3-5: IFPMA General CTD questions & Module 3-5: IFPMA http://www.ich.org http://www.ich.org ctd-related.question@ifpma.org EU-specific Regulatory / Administrative questions Questions on Module 1: EC http://pharmacos.eudra.org/F2/eudralex/vol-2/B/ctdqa_032003.pdf l Aim to maintain harmonised approach l Shared, common interpretation l Refinement of guidance ? 31

32 EU Questions & Answers Q1: onQ1: Guidance on Mixed format applications Q2Q2: Need to reformat old dossiers? Q3Q3: Reformatting = variation? Fee? Q4Q4: Format of Variation applications? Q5Q5: Mixed formats allowed after July 2003? Q6Q6: Format of Line Extensions? Q7Q7: Format of Generic applications? Q8Q8: Module 2 for Generic applications? Q9Q9: Format of Herbal Medicinal Product applicat.? 32

33 EU Questions & Answers Q10:Q10: Format of Mutual Recognition Applications? Q11Q11: Reformatting of MRP dossiers ? Q12Q12: Location of Certificate of Suitability? Q13Q13: Format of bibliographical applications? Q14Q14: Format of EDMFs in CTD applications? Q15Q15: Use of old format EDMFs in CTD applications? Q16Q16: Format of variations to EDMFs? 33

34 EU Questions & Answers Q2 Q2: Need to reformat old dossiers? NO Clinical, non-clinical = not useful Quality = recommended, encouraged -> complete Quality part (incl.DMF if applicable) - > signed declaration from the MAH - > no need for Quality Summary 34

35 EU Questions & Answers Q4 Q4: Format of Variation Application? NO requirement to reformat old dossier - New Variation data = mandatory in CTD - Cross-reference to old data allowed - Copies of approved docs to be provided: take first variation opportunity to reformat the doc / section concerned. 35

36 EU Questions & Answers Q6 Q6: Format of Line Extensions? NO requirement to reformat old dossier - New data = mandatory in CTD - Always Module 1 + 2 - Cross-reference to old data allowed - Follow guidance on mixed applications - MAHs are encouraged to reformat old quality data (may not always be feasible) 36

37 EU Questions & Answers 37 Q10: Q10: Format of Mutual Recognition Applications? If MRP starts after 1 July 2003 CMS will accept the submission of dossiers in the old EU -format until 31 December 2004 MAH to submit reformatted dossier to RMS first. -> no update of the RMS AR necessary -> simple acknowledgement

38 Other EU initiatives l Training for EU EU and CADREAC Assessors (~200): June – July 2001 Quality, Safety, Efficacy workshops l Update of CPMP Assessment Report Templates (available on EMEA Website since March 2002) l Included list of CPMP/ICH guidelines as an Annex to Modules 3-5 38

39 Other EU initiatives EC: Revision of Legislation EC: Revision of Legislation l Update of Annex I to Dir 2001/83/EC to reflect CTD format & terminology implement by July 03 Will be published soon check ECs Website ! l Update of Directive 2001/83/EC as part of the Review proposals: expert reports detailed summaries 39

40 CTD Applications received July 01 – May 03 EMEA (Centralised Procedure): 16 new applications in full CTD format 6 new applications in mixed CTD+old format Of those, 5 concerned Part A products 21 concerned Part B products 9 line extensions (Q only; Q + C) 40

41 l Experience so far is positive l Most questions & issues handled during Pre- Submission contacts with Applicants or during validation of the application. l So far, no feedback from assessors on any difficulties encountered during assessment. l Issues encountered now clarified via Q&A on Web 41 EMEA Experience General issues

42 l No deviations from headings & numbering leave CTD headings & numbering unchanged OK to introduce further sub-headings under existing CTD headings x other deviations refused NO additions NO deletions NO re-numbering 42 EMEA Experience General issues

43 l Sections not applicable or cross-referring to old data to be maintained in dossier structure + commented in Overviews l No new Appendices or Annexes: All information to be included in the relevant sections of Modules 3-5 and not at the end of the Module as new appendices not foreseen in CTD (e.g. stability protocols, validation data). 43 EMEA Experience General issues

44 Advice to Applicants Follow CTD guidance; do not invent or adapt Consult Q&A on ICH and Commissions Website In case of doubt: consult relevant Authority or send questions to ICH / EC mailbox EMEA provides assistance to applicants in the pre-submission stage 44

45 Conclusion - Overall Benefit Common format for applications, to be used in the 3 Regions Requires commitment & (re-)organisation Resource saving for industry Single dossier and Possible simultaneous submissions in the 3 regions Implementation of electronic CTD (e-CTD) More consistent assessment Accelerate availability of new medicines ? 45

46 Useful Websites ICH – CTD Guidelines + Q&A + e-CTD: http://www.ich.org/ich5c.html EU – NTA incorporating the CTD + Q&A: http://pharmacos.eudra.org/F2/eudralex/vol- 2/home.htm#2b http://pharmacos.eudra.org/F2/eudralex/vol- 2/home.htm#2b FDA - Guidance on CTD http://www.fda.gov/cder/guidance/4539O.htm #top http://www.fda.gov/cder/guidance/4539O.htm #top 46


Download ppt "FFUL LisbonHilde Boone 29 May 2003 EMEA 1 Implementation of the CTD in Europe & EMEA Experiences Evaluation and Regulation of Medicines & Health Products."

Similar presentations


Ads by Google